Document is current
Any future updates will be listed below
-
Authors
Desmidt, Thomas https://orcid.org/0000-0003-0949-8389
Dujardin, Paul-Armand
Andersson, Frédéric
Brizard, Bruno https://orcid.org/0000-0002-0110-822X
Réméniéras, Jean-Pierre
Gissot, Valérie https://orcid.org/0000-0002-0091-8159
Arlicot, Nicolas https://orcid.org/0000-0001-7087-2312
Barantin, Laurent https://orcid.org/0000-0002-5119-658X
Espitalier, Fabien
Belzung, Catherine https://orcid.org/0000-0001-6095-5974
Tanti, Arnaud https://orcid.org/0000-0003-4249-2317
Robert, Gabriel https://orcid.org/0000-0003-2490-0700
Bulteau, Samuel
Gallet, Quentin
Kazour, François
Cognet, Sandrine
Camus, Vincent https://orcid.org/0000-0002-6845-221X
El-Hage, Wissam
Poupin, Pierre https://orcid.org/0000-0003-1946-1686
Karim, Helmet T. https://orcid.org/0000-0002-9286-0694
- License Information
-
More Information
Article History
Received: 21 February 2023
Revised: 1 August 2023
Accepted: 3 August 2023
First Online: 17 August 2023
Competing interests
: TD reports personal fees from Janssen and Lundbeck. WEH reports personal fees from Air Liquide, Eisai, Janssen, Lundbeck, Otsuka, UCB and Chugai. VC reports personal fees from Janssen, Bristol Myers Squibb and AA Pharma. All other authors declare no competing interests.
